This content is from: Portfolio Drug Royalty Bonds Attract Investors Drug royalty securitizations have become a valuable source of financing for Vertex Pharmaceuticals. By Udayan Gupta September 02, 2009
This content is from: Research Health Care - Biotechnology: 2011 Third Clients say Sanford C. Bernstein & Co.’s Geoffrey Porges, in third place for a fourth straight year, is “an independent thinker” who “isn’t afraid to break from the crowd.” October 11, 2011
This content is from: Research The 2014 All-America Research Team: Biotechnology, No. 2: Geoffrey Meacham October 07, 2014
This content is from: Portfolio Merck Allocates $500 Million to Venture Capital Biotech investments could restock the drugmaker’s much-depleted pipeline, if more successful than previous efforts. By Udayan Gupta November 01, 2011
This content is from: Portfolio Drug Wars: The Battle to Put a Lid on Rising Prices In the first of five stories on the battle to address skyrocketing drug prices in the U.S., Institutional Investor looks at how the actions of Turing Pharmaceuticals CEO Martin Shkreli set off a firestorm in Washington. By Khadijah M. Silver November 25, 2015
This content is from: Premium These Stocks Attracted the Most New Interest from Hedge Funds Last Quarter While hedge funds mostly stuck with the same stocks in the third quarter, many of them poured into names that are currently off the momentum radar. By Stephen Taub November 27, 2017
